Skip to main
DXCM
DXCM logo

DexCom (DXCM) Stock Forecast & Price Target

DexCom (DXCM) Analyst Ratings

Based on 40 analyst ratings
Buy
Strong Buy 40%
Buy 43%
Hold 18%
Sell 0%
Strong Sell 0%

Bulls say

DexCom has achieved record new patient starts in Q3 2024, reflecting strong demand for its continuous glucose monitoring systems and solid core growth in international markets. The company is projected to see an increase in EBITDA margin from 28% in 2023 to approximately 29% in 2024, with expectations of reaching 31% by 2025, indicating a positive trend in profitability. Additionally, the ongoing expansion of its prescriber base and stabilization in the durable medical equipment channel are expected to contribute to robust sales growth, with projected year-over-year growth of at least 15% in 2025.

Bears say

The negative outlook on DexCom's stock is primarily driven by a 2% year-over-year decline in revenue in the U.S. for the second quarter of 2024, despite a more than 20% increase in the installed base. Additionally, the company has lost incremental market share in the durable medical equipment (DME) channel and is facing pricing pressures as its pricing begins to align more closely with competitors following the integration of automatic insulin delivery systems. Furthermore, management's guidance suggests that future growth in the Type 1 diabetes segment is likely to be more subdued than previously anticipated.

DexCom (DXCM) has been analyzed by 40 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 43% recommend Buy, 18% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of DexCom and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About DexCom (DXCM) Forecast

Analysts have given DexCom (DXCM) a Buy based on their latest research and market trends.

According to 40 analysts, DexCom (DXCM) has a Buy consensus rating as of Jul 1, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $138.91, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $138.91, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

DexCom (DXCM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.